-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Magnetic resonance spectrometry (MRS) is a non-invasive biomarker imaging method, which is widely used to detect the mutation status of brain tumor, diagnosis of glioma and evaluation of tumor invasiveness by analyzing tumor-specific metabolic processes in the body.
Vivek Tiwari of the Center for Advanced Imaging Research at the University of Texas Southwestern Medical Center and others used MRS to detect glycine levels in patients with glioma and to analyze the correlation between tumor progression and clinical prognosis.
results were published in Neuro-Oncology in July 2020.
high-level gliomas meet the nutritional needs of rapid cell proliferation by reshaping metabolic mechanisms.
glycine as an intermediate product of nucleotide biosynthetics, the content increases with cell proliferation.
researchers used MRS to detect glycine, 2-hydroxypropypyt acid (2HG) and other tumor-related metabolites in 35 glioma patients; Levels of glycine and 2HG expression in prosurromas (Figure 1), tumor proliferation and progression increased when glycine content increased (Figure 2), and high glycine/2HG ratios indicated poor survival prognosis in patients (Figure 3).
35 patients with glioma showed levels of glycine and 2HG expression.
2. The relationship between the expression of glycine and 2HG and tumor progression.
Figure 3. Kaplan-Meier analyzes the effects of metabolites and enzyme expression levels on the overall survival of patients.
conclusion The authors conclude that MRS, as a non-invasive secondary testing tool, can predict tumor progression and clinical prognosticity by detecting glycine content.
: The intellectual property rights of the content published by the Brain Medical Exchange's Extra-God Information, God-based Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, the original authors and other relevant rights persons.
, editing, copying, cutting, recording, etc. without permission.
be used with a license, the source must also be indicated.
welcome to forward and share.
。